The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin

British Journal of Haematology

Volumn 154, Issue 4, 2011, Pages 477-481

  Czuczman, Myron S ^a   Vose, Julie M ^b   Witzig, Thomas E ^c   Zinzani, Pier L ^d   Buckstein, Rena ^e   Polikoff, Jonathan ^f   Li, Ju ^g   Pietronigro, Dennis ^g   Ervin Haynes, Annetti ^g   Reeder, Craig B ^h  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f KAISER FOUNDATION HOSPITAL   (United States)

^g CELGENE CORPORATION   (United States)

^h MAYO CLINIC   (United States)

Author keywords

Lenalidomide; Transformed chronic lymphocytic leukaemia; Transformed follicular lymphoma; Transformed lymphoma; Transformed small lymphocytic lymphoma

Indexed keywords

ALANINE AMINOTRANSFERASE; CALCIUM; GAMMA GLUTAMYLTRANSFERASE; LENALIDOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BONE MARROW SUPPRESSION; CALCIUM BLOOD LEVEL; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONVULSION; CYTOLYTIC HEPATITIS; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SEPSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA; TRANSFORMED FOLLICULAR LYMPHOMA; TRANSFORMED SMALL LYMPHOCYTIC LYMPHOMA; TUMOR FLARE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79960834399     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08781.x     Document Type: Article

References (27)

1. Al-Tourah, A.J., Gill, K.K., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Sehn, L.H., Shenkier, T.N., Gascoyne, R.D. & Connors, J.M. (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 5165-5169.
2. Bernstein, S.H. & Burack, W.R. (2009) The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology American Society of Hematology. Education Program, 532-541.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
4. Davies, A.J., Rohatiner, A.Z., Howell, S., Britton, K.E., Owens, S.E., Micallef, I.N., Deakin, D.P., Carrington, B.M., Lawrance, J.A., Vinnicombe, S., Mather, S.J., Clayton, J., Foley, R., Jan, H., Kroll, S., Harris, M., Amess, J., Norton, A.J., Lister, T.A. & Radford, J.A. (2004) Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 22, 1469-1479.
5. Doocey, R.T., Toze, C.L., Connors, J.M., Nevill, T.J., Gascoyne, R.D., Barnett, M.J., Forrest, D.L., Hogge, D.E., Lavoie, J.C., Nantel, S.H., Shepherd, J.D., Sutherland, H.J., Voss, N.J., Smith, C.A. & Song, K.W. (2005) Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. British Journal of Haematology, 131, 223-230.
6. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Wierda, W.G., Estrov, Z., Faderl, S., Cohen, E.N., Li, C., Reuben, J.M. & Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297.
7. Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 8447-8452.
8. Friedberg, J.W., Cohen, P., Chen, L., Robinson, K.S., Forero-Torres, A., La Casce, A.S., Fayad, L.E., Bessudo, A., Camacho, E.S., Williams, M.E., van der Jagt, R.H., Oliver, J.W. & Cheson, B.D. (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. Journal of Clinical Oncology, 26, 204-210.
9. Gaidarova, S., Corral, L.G., Gleizer, E., Young, D., Brady, H., Bennett, B. & Lopez-Girona, A. (2008) Lenalidomide enhances anti-tumor effect of {gamma}{delta} T cells against mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts), 112, 2616.
10. Gorgun, G., Ramsay, A.G., Holderried, T.A., Zahrieh, D., Le Dieu, R., Liu, F., Quackenbush, J., Croce, C.M. & Gribben, J.G. (2009) E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 106, 6250-6255.
11. Hamadani, M., Awan, F.T., Elder, P., Lin, T.S., Porcu, P., Benson, D.M., Blum, K.A. & Devine, S.M. (2008) Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leukaemia & Lymphoma, 49, 1893-1898.
12. Hayashi, D., Lee, J.C., Devenney-Cakir, B., Zaim, S., Ounadjela, S., Solal-Celigny, P., Juweid, M. & Guermazi, A. (2010) Follicular non-Hodgkin's lymphoma. Clinical Radiology, 65, 408-420.
13. Keating, G.M. (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 70, 1445-1476.
14. Micallef, I.N., Remstein, E.D., Ansell, S.M., Colgan, J.P., Inwards, D.J., Johnston, P.B., Lewis, J.T., Markovic, S.N., Porrata, L.F., White, W.L., Witzig, T.E., Ristow, K. & Habermann, T.M. (2006) The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leukaemia & Lymphoma, 47, 1794-1799.
15. Molica, S. (2010) A systematic review on Richter syndrome: what is the published evidence? Leukaemia & Lymphoma, 51, 415-421.
16. Montoto, S., Davies, A.J., Matthews, J., Calaminici, M., Norton, A.J., Amess, J., Vinnicombe, S., Waters, R., Rohatiner, A.Z. & Lister, T.A. (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. Journal of Clinical Oncology, 25, 2426-2433.
17. Noy, A., Schoder, H., Gonen, M., Weissler, M., Ertelt, K., Cohler, C., Portlock, C., Hamlin, P. & Yeung, H.W. (2009) The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Annals of Oncology, 20, 508-512.
18. Ramadan, K.M., Connors, J.M., Al-Tourah, A., Gascoyne, R.D., Song, K.W., Barnett, M.J., Nantel, S.H., Nevill, T.J., Shepherd, J.D., Sutherland, H.J., Lavoie, J., Forrest, D.L., Hogge, D.E., Voss, N., Brinkman, R., Abou Mourad, Y.R., Power, M.M., Narayanan, S., Smith, C.A. & Toze, C.L. (2008) Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma. Blood (ASH Annual Meeting Abstracts), 112, 4459.
19. Relander, T., Johnson, N.A., Farinha, P., Connors, J.M., Sehn, L.H. & Gascoyne, R.D. (2010) Prognostic factors in follicular lymphoma. Journal of Clinical Oncology, 28, 2902-2913.
20. Rezvani, A.R., Storer, B., Maris, M., Sorror, M.L., Agura, E., Maziarz, R.T., Wade, J.C., Chauncey, T., Forman, S.J., Lange, T., Shizuru, J., Langston, A., Pulsipher, M.A., Sandmaier, B.M., Storb, R. & Maloney, D.G. (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 211-217.
21. Rossi, D., Cerri, M., Capello, D., Deambrogi, C., Rossi, F.M., Zucchetto, A., De Paoli, L., Cresta, S., Rasi, S., Spina, V., Franceschetti, S., Lunghi, M., Vendramin, C., Bomben, R., Ramponi, A., Monga, G., Conconi, A., Magnani, C., Gattei, V. & Gaidano, G. (2008) Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 142, 202-215.
22. Tsimberidou, A.M., Kantarjian, H.M., Cortes, J., Thomas, D.A., Faderl, S., Garcia-Manero, G., Verstovsek, S., Ferrajoli, A., Wierda, W., Alvarado, Y., O'Brien, S.M., Albitar, M., Keating, M.J. & Giles, F.J. (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer, 97, 1711-1720.
23. Tsimberidou, A.M., Wierda, W.G., Plunkett, W., Kurzrock, R., O'Brien, S., Wen, S., Ferrajoli, A., Ravandi-Kashani, F., Garcia-Manero, G., Estrov, Z., Kipps, T.J., Brown, J.R., Fiorentino, A., Lerner, S., Kantarjian, H.M. & Keating, M.J. (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 26, 196-203.
24. Wiseman, G.A., White, C.A., Sparks, R.B., Erwin, W.D., Podoloff, D.A., Lamonica, D., Bartlett, N.L., Parker, J.A., Dunn, W.L., Spies, S.M., Belanger, R., Witzig, T.E. & Leigh, B.R. (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology/hematology, 39, 181-194.
25. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N., Grillo-Lopez, A.J., Multani, P. & White, C.A. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 2453-2463.
26. Witzig, T.E., Wiernik, P.H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J.B. & Vose, J.M. (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 5404-5409.
27. Witzig, T.E., Vose, J.M., Zinzani, P.L., Reeder, C.B., Buckstein, R., Polikoff, J.A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., Pietronigro, D., Ervin-Haynes, A.L. & Czuczman, M.S. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Annals of Oncology, doi: 10.1093/annonc/mdq626.